EUVIMEDEUVIMED entdecken
Crossref

Cardiac contractility modulation therapy in patients with implanted cardiac resynchronization therapy: results of the 2 year follow-up

K. V. Davtyan, N. A. Mironova, I. A. Chugunov, E. M. Gupalo, A. G. Topchyan

Journal of Arrhythmology · 2023

DOI: 10.35336/va-1145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Arrhythmology, 2023. Verfasst von K. V. Davtyan und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Cardiac contractility modulation (CCM) is a device therapy for patients with heart failure with reduced ejection fraction (HFrEF), most of the data on its programming are concerned patients with narrow QRS and of limited follow up. Our aim was to propose programming approach for Optimizer device in setting of wide QRS complex and fragmented ventricular local activation.

Methods

We enrolled 11 patients with HFrEF (median age, 8 males, median NYHA class 3) and LBBB-related wide QRS complex, who underwent Optimizer™ device implantation. Three patients got Optimizer™ IV system and eight patients were implanted Optimizer™ Smart. Ten patients were previously implanted with CRT-D due to HFrEF and LBBB; one patient received CRT-D after Optimizer™ implantation.

Results

During the implantation procedure ventricular local sense (LS) channel signal fragmentation was detected in all patients. In five patients signal detection was optimized by lead relocation. In six patients LS signal sensitivity limitations were resolved by programming. At two-year follow-up survival 4 patients died of noncardiac causes (1 intracranial hemorrhage, 1 gastrointestinal bleeding and 2 - terminal kidney failure). At 12-month follow-up we observed a non-significant improvement in 6-minute walking distance (300 vs 305, p=0.093), NYHA class (2.75 vs 2, p=0.085), MLHF score (53 vs 42, p=0.109) and left ventricular ejection fraction (LVEF) (30 vs 33.5, p=0.212).

Conclusion

CCM system implantation is feasible and safe in patients with HFrEF and LBBB-related wide QRS complex. Device programming maneuvers can resolve the challenges of ventricular local signal detection in these patients.

Zitieren

APA

Davtyan, K. V., Mironova, N. A., Chugunov, I. A., Gupalo, E. M., & Topchyan, A. G. (2023). Cardiac contractility modulation therapy in patients with implanted cardiac resynchronization therapy: results of the 2 year follow-up. Journal of Arrhythmology. https://doi.org/10.35336/va-1145

Vancouver

Davtyan KV, Mironova NA, Chugunov IA, Gupalo EM, Topchyan AG. Cardiac contractility modulation therapy in patients with implanted cardiac resynchronization therapy: results of the 2 year follow-up. Journal of Arrhythmology. 2023. doi:10.35336/va-1145

BibTeX
@article{Davtyan2023,
  author = {Davtyan, K. V. and Mironova, N. A. and Chugunov, I. A. and Gupalo, E. M. and Topchyan, A. G.},
  title = {Cardiac contractility modulation therapy in patients with implanted cardiac resynchronization therapy: results of the 2 year follow-up},
  journal = {Journal of Arrhythmology},
  year = {2023},
  doi = {10.35336/va-1145}
}
Kostenlos starten →